Search Results Search Sort by RelevanceMost Recent Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411. Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411. In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411. Health Law May 2005 When a Parent's Religious Belief Endangers Her Unborn Child Faith Lagay, PhD US case law protects a woman's right to refuse life-sustaining medical treatment for her fetus on religious grounds. Virtual Mentor. 2005;7(5):375-378. doi: 10.1001/virtualmentor.2005.7.5.hlaw1-0505. Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 1 Hasan Shanawani, MD, MPH Physicians should understand the ethical issues surrounding assisting patients who receive Medicare- and Medicaid-funded health care. Virtual Mentor. 2005;7(7):469-473. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507. Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 2 Kathleen Nathan Lowe, MSW, ACSW, CMSW Physicians should understand the ethical issues surrounding assisting patients who receive Medicare- and Medicaid-funded health care. Virtual Mentor. 2005;7(7):473-475. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507. State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412. Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572. Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562. Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520. Pagination First page « First Previous page ‹ Previous … Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Current page 29 Page 30 Page 31 Next page Next › Last page Last »
Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411.
Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411.
In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411.
Health Law May 2005 When a Parent's Religious Belief Endangers Her Unborn Child Faith Lagay, PhD US case law protects a woman's right to refuse life-sustaining medical treatment for her fetus on religious grounds. Virtual Mentor. 2005;7(5):375-378. doi: 10.1001/virtualmentor.2005.7.5.hlaw1-0505.
Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 1 Hasan Shanawani, MD, MPH Physicians should understand the ethical issues surrounding assisting patients who receive Medicare- and Medicaid-funded health care. Virtual Mentor. 2005;7(7):469-473. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507.
Case and Commentary Jul 2005 Is Greenacres (Skilled Nursing Facility) the Place to Be? Commentary 2 Kathleen Nathan Lowe, MSW, ACSW, CMSW Physicians should understand the ethical issues surrounding assisting patients who receive Medicare- and Medicaid-funded health care. Virtual Mentor. 2005;7(7):473-475. doi: 10.1001/virtualmentor.2005.7.7.ccas3-0507.
State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412.
Medicine and Society Jul 2024 What Would Equitable Harm Reduction Look Like? Oluwole Jegede, MD, MPH, Julio C. Nunes, MD, Terence Tumenta, MD, MPH, Carmen Black, MD, and Joao P. DeAquino, MD Structural determinants of health frameworks must be person centered and express antiracism to be effective. AMA J Ethics. 2024;26(7):E572-579. doi: 10.1001/amajethics.2024.572.
Medicine and Society Jul 2024 How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder? Elizabeth Salisbury-Afshar, MD, MPH, Catherine J. Livingston, MD, MPH, and Ricky N. Bluthenthal, PhD Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities. AMA J Ethics. 2024;26(7):E562-571. doi: 10.1001/amajethics.2024.562.
Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. AMA J Ethics. 2024;26(7):E520-526. doi: 10.1001/amajethics.2024.520.